Introduction
Virotherapy, where a virus is designed to specifically kill tumour cells but not normal cells presents a promising trajectory for cancer therapy. Numerous studies have shown that different human viruses can suppress the growth of tumour cells (Russell et al., 2012) and among these, human adenoviruses (HAdVs) have emerged as one of the more attractive candidates since they can be grown to high titres, are easy to genetically modify and have the ability to transduce a wide variety of cells, without integrating into the genome. Clinical studies have also given promising results showing that oncolytic HAdVs can be both safe and efficient (Hemminki, 2014) . Non-replicating HAdV vectors armed with suicide genes have the drawback of limited access to all cells within a tumour. In contrast, replicating HAdVs (and preferably conditionally restricted replicating HAdVs) have the capacity for sequential multiplication, release and infection of surrounding cells.
HAdVs show strict host specificity and preclinical research on clinically useful replicating HAdV vectors has been hampered by the lack of an experimental animal model system that can efficiently support HAdV infection and replication. Semi-permissive infections in rodents have been achieved, but the efficiency of wild type HAdV replication is modest (Hallden, 2003; Jiang et al., 2014; Thomas et al., 2006) , although it can be enhanced by transgenic expression of surface receptors and viral genes (Kang et al., 2014; Young et al., 2012) . Thus, the antitumour efficacy of oncolytic HAdV is normally analysed in human xenografts in immunodeficient mice.
We have previously identified a mouse mammary epithelial cell line, NMuMG, that supports HAdV-2 replication to the same level as observed in commonly used and highly permissive human cell lines, like the lung carcinoma cancer cell line A549 (Wu et al., 2013) . NMuMG cells form well-structured and contact-inhibited monolayers and are unable to establish tumours in immunodeficient mice (Hynes et al., 1985) . In contrast, we show here that SV40 T antigen-transformed NMuMG cells (NMuMG-T) readily formed tumours in SCID mice, and that these tumours were highly permissive to HAdV-2 replication and responded by a significantly reduced tumour growth and signs of cellular destruction.
Results and discussion

Establishment of the SV40 T-antigen-transformed cell line NMuMG-LT
The NMuMG cell line is derived from normal mouse mammary epithelial cells and retains the growth characteristics of nontransformed primary cells. We recently demonstrated that the Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/yviro NMuMG cells in tissue culture exhibit an amazing capacity to support replication by a number of HAdV types (Wu et al., 2013) . Since NMuMG cells are essentially non-tumorigenic after transplantation in mice (Hynes et al., 1985) the ability to analyse the oncolytic properties of HAdV required establishment of a tumorigenic NMuMG cell line. For this purpose, NMuMG cells were infected with an SV40 T-expressing retrovirus (Jat et al., 1986) and after G418 selection, the polyclonal NMuMG-T cells were expanded and the expression of the LT protein was analysed by western blotting (Fig. 1A) . Additionally, the growth kinetics and cell morphology of NMuMG-T were analysed and compared to the parental NMuMG cell line. SV40 T antigen expression resulted in cells becoming smaller and growing in less organized foci, thus more similar to a transformed phenotype (Fig. 1B) . Furthermore, the proliferation rate (Fig. 1C ) and saturation density (not shown) of NMuMG-T cells increased dramatically.
To compare the capacity of NMuMG and NMuMG-T to establish tumours, 4 Â 10 6 cells were implanted subcutaneously in the right hind flank of SCID mice. Although implants of the parental NMuMG cells caused a palpable mass after 3-4 weeks, this mass disappeared over time. At the termination of the experiment (day 49) no tumour mass could be recovered from mice implanted with NMuMG cells. In contrast, implanted NMuMG-T cells continued to grow throughout the experiment and at the end of the experiment (day 49), tumour masses with an average size of 150 mm 3 (approximately 0.2 g) were recovered at the site of injection (Fig. 1D) . These results agree with previous reports describing that non-tumorigenic NMuMG cells gained the capacity to generate tumours in immunodeficient mice following introduction of an activated H-ras gene or the polyoma middle T antigen, respectively (Hynes et al., 1985; Salomon et al., 1987) .
Efficient virus production in HAdV-2-infected NMuMG-T cells
We have previously shown that HAdV-2 infected NMuMG cells are as efficient as human A549 cells in producing infectious viral progeny (Wu et al., 2013) . PCR analysis of viral early (E1A) and late (L3) mRNA expression ( Fig. 2A) , as well as western blot analysis of late viral proteins (Fig. 2B ) demonstrated that infection of NMuMG-T cells similarly allowed efficient HAdV-2 replication. To ensure that NMuMG-T cells also supported HAdV-2 virus production, we compared the production of infectious virus particles following infection of NMuMG and NMuMG-T cells (Fig. 2C) . Five million cells were infected with 10 FFU per cell (Philipson, 1961) of HAdV-2 and 48 and 60 h post-infection (pi), intracellular virus particles were isolated and titrated using a limited dilution assay. The produced number of infectious virus particles per cell ('burst size') was almost identical in NMuMG and NMuMG-T cells (Fig. 2C ). In agreement with our previous results (Wu et al., 2013) , the burst size increased 3-4 fold between 48 and at 60 h pi (Fig. 2C) . Thus, virus production in NMuMG and NMuMG-T cells is by far the most efficient that has been described in a mouse cell line so far. Varying, but generally quite modest levels of virus replication have been demonstrated in different murine cell lines (Ganly et al., 2000; Hallden, 2003) . A recent report describes a murine lung adenocarcionoma that supports replication of the oncolytic human adenovirus AdTAV-255 (Zhang et al., 2014) . Since this study did not correlate the replication efficiency of AdTAV to that of wild-type HAdV it is difficult to compare efficiencies. However, from the presented data it appears that the burst size is significantly smaller than what we observe in NMuMG-T cells.
The coxsackie and adenovirus receptor (CAR) is the primary receptor for most HAdVs, including HAdV-2 (Bergelson et al., 1997) and the infection efficiency of tissue culture cells by CARdependent HAdV vectors correlates with CAR-expression. In the human host, CAR is primarily expressed in tight junctions and on the basolateral membrane and therefore not easily accessible for HAdV upon the first encounter with an epithelium (Philipson and Pettersson, 2004) . However, CAR exists in different splice variants, one of which is present on the apical surface of a polarized epithelium and might mediate the initial binding of HAdV (Excoffon et al., 2010) . Down-regulation of CAR expression during malignant progression has been demonstrated in different human cancers (Matsumoto et al., 2005) . However, up-regulated CAR expression has also been described and the discrepant results might possibly represent alternative regulation of the different splice isoforms (Dietel et al., 2011) . Generally, down-regulated CAR expression causes resistance to HAdV oncolytic therapy (Li et al., 1999; Wunder et al., 2012) . In agreement with earlier reports (Vincent et al., 2009 ) our western blot analysis showed that NMuMG cells express CAR (Fig. 2D) . Notably, expression of SV40 T in NMuMG-T correlated with a significantly reduced expression of CAR (Fig. 2D) . No CAR expression was detected in 3T6 cells serving as a negative control. Surprisingly, the reduced CAR expression level in NMuMG-T cells compared to NMuMG did not impair the ability of HAdV-2 to infect (Fig. 2C ), suggesting that CAR was still present in non-limiting amounts on the cell surface or that infection was mediated by alternative receptors. Strikingly, a strong repression of CAR expression was seen upon HAdV-2 infection of both NMuMG and NMuMG-T cells (Fig. 2D ). HAdV infection of human cells has been shown to reduce CAR expression in persistently infected lymphocytes, both at the level of reduced cell surface expression and through transcriptional repression (Zhang et al., 2010) . While the initial elimination of CAR from the cell surface might depend on its interaction with the adenovirus fiber protein (Zhang et al., 2010) , transcriptional silencing of CAR in human cancer cells appears to involve histone deacetylase activity (Wunder et al., 2012) . At the moment it is not clear how the observed repression of CAR in NMuMG and NMuMG-T cells occurs, but based on previous reports describing a shift towards transcriptional silencing of host cell genes during the late phase of HAdV infection it may not be unreasonable to assume that the promoter activity of CAR is repressed (Zhao et al., 2007) .
HAdV-2 reduces growth of NMuMG-T-induced tumours in SCID mice.
To analyse if HAdV-2 could cause cytolytic replication also in tumours established by NMuMG-T, we performed a pilot experiment where 4 Â 10 6 cells were implanted subcutaneously into the right hind flank of SCID mice. When the tumours had reached an average size of 150 mm 3 , the mice were divided into three groups and injected intratumorally with 30 ml PBS (two mice), or PBS containing 10 9 encapsidated viral genomes of UV-inactivated HAdV-2 (two mice) or active HAdV-2 (three mice), respectively. The injections were repeated after seven days and tumour growth was measured every third day until the animals were sacrificed (Fig. 3A) . Both HAdV-2 and UV-inactivated HAdV-2 initially reduced tumour growth, but at the end of the experiment, a clear reduction in tumour size was only seen in mice receiving active HAdV-2 ( Fig. 3A and B) . The initial reduction in tumour growth following injection of UV-inactivated HAdV-2 might indicate that the inactivation step was incomplete. This possibility was supported by the detection of low amounts of viral DNA in mouse blood drawn at day 43 (inset Fig. 3A) . Additionally, it is also possible that viral proteins from the UV-inactivated virus exerted a general inhibitory effect on cell proliferation, but that this gradually disappeared as the virus was eliminated. At the end of the experiment no significant difference in tumour size between injections with PBS alone and UV-inactivated HAdV-2 was seen (Fig. 3B) . In a second experiment, 12 SCID mice were implanted subcutaneously with the NMuMG-T cells into the right hind flank. Following establishment of the tumours, the mice were divided into two groups that received five injections (on day 21, 24, 27, 33 and 36) with either HAdV-2 or PBS, respectively. Tumour growth was followed by caliper measurement every third day. Mice injected with HAdV-2 exhibited a clear reduction in tumour growth compared to mice treated with PBS alone (Fig. 3C) . At day 57 when the experiment was terminated, the tumours were excised, measured and weighed. Except for one outlier, tumours from the HAdV-2-treated mice were significantly smaller in size (Fig. 3D ) and weighed less (Fig. 3E ) than tumours from PBS-treated mice. It should be noted that, for unknown reasons one mouse treated with HAdV-2 died prematurely.
NMuMG-T-induced tumours support replication of HAdV-2
NMuMG cells are derived from mouse mammary gland epithelium and can thus be identified by immunofluorescent staining using epithelial-specific anti-keratin antibodies. In the absence of a virus infection the tumours established by NMuMG-T cells displayed characteristics of duct/gland structures ( Fig. 4A and S1 ). These tumours were generally well structured and lacked signs of necrosis or disintegrated areas, but showed occasional interspersed regions of non-epithelial (negative for keratin) host stroma cells (arrows in Fig. 4A ) and blood vessels (CD31 positive) (Fig. S1 ). In contrast, the tumours treated with HAdV-2 were less structured and also exhibited areas with disruption of the tumour tissue structures, suggestive of extensive necrosis (Fig. 4B) . In tumours injected with HAdV-2, hexon production overlapped with keratin-expressing cells indicating that the virus replicated specifically in NMuMG-T cells. As expected, interspersed nonepithelial host cells in the tumours did not stain for hexon (marked by arrow in Fig. 4B ) demonstrating that only NMuMG-T cells were able to support virus replication. This was further illustrated by imaging areas with pronounced infiltration of nonepithelial recipient mouse cells with enhanced signal intensity (Fig. S2 ) and at higher magnification (Fig. S3) . Notably, the intensity of the keratin staining was consistently higher in all the virusinjected tumours than in the PBS-injected tumours, possibly Fig. 3A . After 61 days the experiment was terminated and the mice were sacrificed. The volume of the excised tumours was determined. (C) Effect of repeated HAdV-2 injections on NMuMG-T tumour growth. HAdV-2 or PBS was injected into NMuMG-T tumours at the time points indicated by the arrows and the size of the tumours was estimated every third day. The data represent mean values 7 standard deviation between all mice within each group (six and five mice, respectively). (D and E) The end size of the tumours in Fig. 3C . After 57 days the experiment was terminated and the mice sacrificed. The volume (D) and weight (E) of the excised tumours were determined. reflecting cytopathic effects causing altered antigen exposure ( Fig. 4A and B, Fig. S3A and C) .
Without expression of a therapeutic transgene it is assumed that an efficient oncolytic capacity of HAdV relies on continuous virus infection, replication, cytolysis and release of produced virus. Immunostaining of excised tumours demonstrated that the HAdV-2 hexon protein was expressed three weeks after the last injection of virus (Fig. 4B, S2 and S3 ), strongly suggesting an efficient and sustained viral replication. The highly permissive nature of NMuMG-T cells for HAdV infection agrees with the observation that the majority of analysed sections of NMuMG-T-established tumour cells stained positive for hexon expression. In the tumour sections, the localization of hexon appeared to vary from mainly cytoplasmic to throughout the cell (Fig. S2) . Although the state of the infected cells in the tumour sections was not addressed beyond determining their origin as NMuMG-T cells, it is possible that the differential localization reflects that some cells were dead or dying, whereas others were still alive but at a late stage of infection.
To verify a sustained replication of HAdV, the excised tumours were used for extraction of viral DNA and proteins. PCR amplification demonstrated that all tumours from mice subjected to intratumoural injection of HAdV-2 contained viral DNA (Fig. 5A ). Quantitative PCR analysis showed an extensive viral DNA replication in two of the tumours (between 10 9 and 10 10 viral genomes/mg tissue), moderate in one and modest in two (Fig. 5B ). In agreement with these results, viral structural proteins were easily detectable in the three tumours with the highest amount of viral DNA, whereas lower amounts of viral proteins were observed in the two samples with limited viral DNA replication (Fig. 5C ). To our knowledge, sustained HAdV replication following injection of tumours established in mice has not been described before. We find this result interesting since repetitive rounds of viral replication is desirable to obtain extensive HAdV-mediated killing of solid tumours.
PCR analyses failed to demonstrate detectable amounts of viral DNA in lung, spleen or kidney, in any of the animals injected with HAdV-2 (Fig. 5D) , suggesting that any systemic distribution of virus from the tumour that may occur did not result in virus replication at these sites. In the two mice showing the strongest intratumoral virus replication (Fig. 5A, mouse 1 and 5) , the liver contained detectable amounts of viral DNA (Fig. 5D) . However, no late viral proteins could be detected by western blotting in the liver (data not shown) suggesting that viral replication did not occur in livers but that the DNA was more likely taken up by the liver cells from the circulatory system. This is also consistent with the general inability of HAdV to replicate in mice and the apparent lack of viral protein production in the cells surrounding the tumour tissues (Fig. 4B) .
In summary, this study demonstrates that a tumorigenic derivative of NMuMG cells can support replication of HAdV-2 when grown as tissue culture cells and, more importantly, also after establishment of tumours in mice. Ongoing replication was observed three weeks after the final injection of HAdV-2. This correlated with a slow tumour growth and signs of disruption of tumour structures. NMuMG cells are derived from the mouse strain Namru (Owens et al., 1974) . Despite extensive efforts, we have not been able to retrieve this strain. We do however believe that the combination of NMuMG-T cells and Namru (or a another syngenic mouse strain) would offer an ideal model system for the expanded investigation of the efficacy of oncolytic HAdVs.
Materials and methods
Establishment of NMuMG-T cells
NMuMG cells were infected for 4 h at 37°C with a recombinant retrovirus that transduce the SV40 T gene along with a neomycinresistance marker gene (Jat et al., 1986) Transduced cells were obtained after selection with G418 (400 μg/ml). A population of cells with stable expression of SV40 T protein was verified by western blot analysis using an anti-LT antibody (Pallas et al., 1986) . The resulting cell line was termed NMuMG-T.
Adenovirus infection
NMuMG and NMuMG-T cells were mock-infected or infected in serum-free DMEM with HAdV-2 at a multiplicity of 10 FFU per cell (Philipson, 1961) . After adsorption for one hour at 37°C in humidified air with 5% CO 2 , the medium was replaced with DMEM supplemented with 2% FBS and the infected cells were further incubated at 37°C in 5% CO 2 . At indicated time points cells were harvested by trypsin/EDTA treatment and the cell pellets were snap frozen for further RNA, DNA and/or protein extraction.
Tumour models and virus attack
Five weeks old female SCID mice were housed at the BMC animal facility (Uppsala, Sweden) in individually ventilated cages (two mice per cage). NMuMG-T cells were suspended in ice-cold PBS buffer and 4 Â 10 6 cells in a total volume of 100 μl were implanted subcutaneously in the right hind flank. Mice were treated with intratumoural injections of 30 μl PBS with or without 1 Â 10 9 encapsidated viral genomes of HAdV-2. UV inactivation of HAdV-2 was performed essentially as described in (Stein and Falck-Pedersen, 2012) by irradiating the virus sample at 365 nm for 20 min in the presence of 1 mg/ml of Psoralen (Sigma, Germany). Tumour growth was monitored by caliper measurement and the tumour volume was calculated using the ellipsoid volume formula (length Â width Â depth Â π/6). Blood was collected from the tail vein of the mice and DNA was isolated using QIAamp DNA blood Mini kit (Qiagen). The mice were sacrificed before the tumours reached a size larger than 900 mm 3 . Tumour, liver, spleen and lung samples from each mouse were isolated separately. A part of each sample was snap frozen for DNA and protein extraction, and the remaining tissues were fixed in 4% formalin for analysis by immunostaining.
DNA and RNA preparation and PCR analysis
To prepare DNA, collected tissue culture cells were resuspended in lysis buffer (100 mM NaCl, 10 mM Tris-HCl pH 8.0, 25 mM EDTA pH 8.0, 0.5% SDS and 250 mg/ml proteinase K) and treated for 2 h at 37°C. The samples were centrifuged at 12,000 rpm for 30 min, the supernatants were transferred to new tubes and ethanol-precipitated. The DNA pellets were suspended in TE-buffer. DNA from mouse tissues was isolated using the same method except for addition of a first step where the frozen samples were thawed and grinded in lysis buffer.
PCR amplification of viral DNA was performed in a thermocycler using 100 ng of DNA in a total volume of 25 ml using primers for HAdV-2 E1A 5 0 -GTGCCAGCGAGTAGA-3 0 and 5 0 -GTCAGAAAACC TGGT-3 0 , and mouse actin 5 0 -GGCTGTATTCCCCTCCATCG-3 0 and 5 0 -CCAGTTGGTAACAATGCCATGT-3 0 . The PCR reaction conditions were: 95°C 5 min, (95°C for 20 s, 58°C for 20 s and 72°C for 20 s) Â 30 cycles, and 72°C 10 min. The PCR products were analysed by electrophoresis in 1.2% agarose gels.
The QPCR was performed using 50 ng DNA and iQTM SYBR Green Supermix (Bio-Rad) in a Miniopticon Real-Time PCR System (Bio.Rad, CFB-3120) and the E1A primers described above. Cycles conditions were 95°C 10 min (95°C for 15 s, 58°C for 20 s, and 72°C for 20 s) Â 40. All samples were analysed in technical triplicate.
Preparation of mRNA from tissue culture cells, cDNA synthesis and PCR were performed as described before (Wu et al., 2013) .
Protein preparation and western blot analysis
Collected cell pellets were lysed on ice for 30 min in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% deoxycholate, 1% Tween-20 and protease inhibitors (Roche)). Frozen tumour samples were cut into pieces with a razor blade, grinded in RIPA buffer and lysed on ice for 30 min. Lysates were centrifuged at 12,000 rpm for 10 min at 4°C, and the supernatants were collected. 15 μg of protein lysate was mixed with 2 Â Laemmli sample buffer (62.5 mM Tris-HCl pH 6.8, 25% glycerol, 0.01% BFB and 2% SDS), boiled for 5 min and separated by SDS-PAGE (10%). Following blotting onto an Immobilon-FL Transfer Membrane (Millipore), the membranes were probed with polyclonal antibodies directed against purified HAdV-2 (ab6982, Abcam), (Prage et al., 1970) , β-actin (I-19, sc-1616, Santa Cruz), SV40 T-antigen (Pallas et al., 1986) , CAR (ad153740, Abcam).
End-point dilution assay
Five million NMuMG-T cells were seeded in 10 cm tissue culture plates and 18 h later infected with HAdV-2 at a multiplicity of 10 FFU/cell (Philipson, 1961) . Cell pellets were collected at 48 h and 60 h pi, respectively. The pellets were suspended in 1 ml serum-free medium, freeze-thawed three times and cleared from debris by centrifugation at 10,000g in an Eppendorf centrifuge. The supernatants were diluted to 10 ml in serum-free medium and filtered (0.45 μm, Millipore). Each sample was titrated by the limiting dilution method (tissue culture inhibitory dose at 50%: TCID50) on sub-confluent monolayers of NMuMG or NMuMG-T cells in 96-well plates (10 4 cells/well). Infected plates were incubated at 37°C in humidified air containing 5% CO 2 for 6 days at which the wells showing a cytopathic effect were determined using a DMRIB inverted microscope (Lecia). Each assay was repeated three times and the virus titres expressed as infectious particles/cell 7SD (Wu et al., 2013) Immunohistochemistry following HAdV-2 attack on tumours
Cryosections (5 μm) of formalin-fixed tumours were stained with rabbit polyclonal anti-keratin antibody (C2562, SigmaAldrich), mouse anti-hexon antibody (MAB8052, Millipore) and anti-CD31 antibody (553370; BD Pharmingen; BD Biosciences). Secondary goat anti-rabbit antibodies conjugated with Alexa Fluor 594 (Life Technologies, 1:1000) or goat anti-mouse conjugated with Alexa Fluor 488 (Life Technologies, 1:400) were used. Nuclei were visualized with Hoechst (H1399, Invitrogen, 1:1000). ProLong Gold anti-fade reagent (1389854, Life Technologies) was used to mount stained sections. Pictures were taken with a Nikon Eclipse 90i microscope, using the 20 Â or 40 Â objectives and the NIS Elements 3.2 software with the same exposure time for all samples.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism software version 5.01 (GraphPad software, San Diego, CA). Tumour size in different treatment groups were compared by using twoway analysis of variance.
Biosafety level and ethics declaration
All experiments using HAdV2 were conducted under biosafety level 2 and approved by The Swedish Work Environment Authority. The Uppsala Animal Ethics Committee approved the animal studies (C215/12).
